

On page 9, line 24, before "microcrystalline",  
insert a ---,--.

R E M A R K S

The specification was amended in order to correct minor clerical errors. No new matter has been introduced.

With further regard to Example 2 in the above-identified application (see pages 12 to 13), further testing has revealed the results of the activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against the human immunodeficiency virus HIV (HTLV-III LAV) and the  $ED_{50}$  is  $8.8 \times 10^{-3} \mu\text{M}$  ( $ED_{50}$  is defined on page 14 of the application). In the patent application, the three levels of compound tested were 1, 10 and 100  $\mu\text{M}$ . This was extended to lower concentrations as follows:

| <u>Concentration (uM)</u> | <u>Percent Inhibition</u> |
|---------------------------|---------------------------|
| 0.001                     | 11                        |
| 0.01                      | 64                        |
| 0.1                       | 81                        |
| 1.0                       | 99                        |
| 10.0                      | 100                       |

Respectfully submitted,  
SPRUNG HORN KRAMER & WOODS

By Richard S. Barth  
Richard S. Barth  
Reg. No. 28,180

600 Third Avenue  
New York, NY 10016  
(212) 661-0520